Trials / Completed
CompletedNCT02131493
S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer
A Open-label, Randomized Study of S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, open-label, controlled study that will compare the efficacy of S-1 in combination with gemcitabine to gemcitabine alone as adjuvant treatment for patients with surgically resected pancreatic adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-1, Gemcitabine |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2021-06-01
- Completion
- 2021-12-01
- First posted
- 2014-05-06
- Last updated
- 2022-03-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02131493. Inclusion in this directory is not an endorsement.